{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:26:09Z","timestamp":1784921169048,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"LiPlasome Pharma A\/S"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.ejca.2010.07.015","type":"journal-article","created":{"date-parts":[[2010,8,27]],"date-time":"2010-08-27T10:11:17Z","timestamp":1282903877000},"page":"3016-3021","source":"Crossref","is-referenced-by-count":83,"title":["Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation"],"prefix":"10.1016","volume":"46","clinical-trial-number":[{"clinical-trial-number":"2006-006637-40","registry":"10.18810\/euctr"}],"author":[{"given":"Maja J.A.","family":"de Jonge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije","family":"Slingerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.","family":"Loos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.C.","family":"Wiemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith R.","family":"Kroep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margret A.G.","family":"den Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"van der Biessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Ho","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejca.2010.07.015_bib1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/sj.bjc.6600884","article-title":"Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients","volume":"88","author":"de Jongh","year":"2003","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2010.07.015_bib2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.1999.17.1.409","article-title":"Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin","volume":"17","author":"Go","year":"1999","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2010.07.015_bib3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/bjc.1993.429","article-title":"Phase I\/II study of a short course of weekly cisplatin in patients with advanced solid tumours","volume":"68","author":"Planting","year":"1993","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2010.07.015_bib4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1634\/theoncologist.2007-0180","article-title":"Concept and clinical evaluation of carrier-mediated anticancer agents","volume":"13","author":"Zamboni","year":"2008","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.ejca.2010.07.015_bib5","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6603345","article-title":"Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer","volume":"95","author":"White","year":"2006","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2010.07.015_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00280-003-0719-4","article-title":"Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma","volume":"53","author":"Zamboni","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"10.1016\/j.ejca.2010.07.015_bib7","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1359-6446(03)02754-5","article-title":"Phospholipase A2 expression in tumours: a target for therapeutic intervention?","volume":"8","author":"Laye","year":"2003","journal-title":"Drug Discov Today"},{"issue":"3","key":"10.1016\/j.ejca.2010.07.015_bib8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/(SICI)1097-0215(19970620)74:3<245::AID-IJC2>3.0.CO;2-Z","article-title":"Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer","volume":"74","author":"Abe","year":"1997","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2010.07.015_bib9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.plipres.2004.12.001","article-title":"Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release","volume":"44","author":"Andresen","year":"2005","journal-title":"Prog Lipid Res"},{"issue":"11","key":"10.1016\/j.ejca.2010.07.015_bib10","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1535-7163.1451.3.11","article-title":"Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids","volume":"3","author":"Jensen","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2010.07.015_bib11","unstructured":"<http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf>."},{"key":"10.1016\/j.ejca.2010.07.015_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment of solid tumours","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.ejca.2010.07.015_bib13","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1200\/JCO.2000.18.10.2104","article-title":"Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects","volume":"18","author":"de Jonge","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"10.1016\/j.ejca.2010.07.015_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000046589","article-title":"Thrombotic microangiopathy in the cancer patient","volume":"106","author":"Kwaan","year":"2001","journal-title":"Acta Haematol"},{"issue":"4","key":"10.1016\/j.ejca.2010.07.015_bib15","first-page":"589","article-title":"Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study","volume":"13","author":"Stathopoulos","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2010.07.015_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2009.07.1733","article-title":"Concurrent liposomal cisplatin (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I\/II study","author":"Koukourakis","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2010.07.015_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2165\/00003495-199700544-00007","article-title":"Safety aspects of pegylated liposomal doxorubicin in patients with cancer","volume":"54","author":"Alberts","year":"1997","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejca.2010.07.015_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00280-004-0852-8","article-title":"Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients","volume":"55","author":"Urien","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.ejca.2010.07.015_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002800100371","article-title":"Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin","volume":"49","author":"Meerum Terwogt","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1016\/j.ejca.2010.07.015_bib20","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1200\/JCO.1986.4.9.1392","article-title":"Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin","volume":"4","author":"Reece","year":"1986","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910006933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910006933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T01:11:55Z","timestamp":1685754715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910006933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":20,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0959804910006933"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.07.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}